Document Detail


Pertussis in adolescents.
MedLine Citation:
PMID:  17565926     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pertussis is a highly communicable respiratory infection caused by Bordetella pertussis. In spite of the widespread availability of effective vaccines and high levels of vaccination coverage, a significant resurgence in pertussis has been observed during the past 2 decades. The increase in reported cases is due in large part to infection in adolescents and adults, and waning immunity plays an important role. Pertussis in adolescents and adults often goes unrecognized because a persistent, uncharacteristic cough might be the only clinical presentation. Pneumonia is the most frequent complication. Culture and polymerase chain reaction are helpful in establishing the diagnosis if a specimen can be obtained early in the course of the illness. Serology is useful when the diagnosis is not suspected until a later stage. Treatment with a macrolide antibiotic is recommended for affected individuals, as well as for all household and other close contacts. Universal immunization is necessary for disease control. Immunization should begin in infancy and should continue with booster doses through adulthood. Two adolescent and adult formulations of acellular pertussis vaccine are licensed in North America and Europe. Both are combined with an adult formulation of diphtheria and tetanus toxoids. In the US, Adacel (Sanofi Pasteur, Toronto, Ontario, Canada) is licensed for use in individuals aged 11 to 64 y while Boostrix (GlaxoSmithKline Biologicals, Rixensart, Belgium) is licensed for use in individuals aged 10 to 18 y. These vaccines are safe, immunogenic, and well tolerated. Routine vaccination of adolescents and adults is required for optimal control of pertussis.
Authors:
Alexander K C Leung; William Lane M Robson; H Dele Davies
Related Documents :
17854476 - Characterization of bordetella pertussis clinical isolates that do not express the trac...
20700556 - Pertussis in portugal - time for a new strategy.
18987746 - Association of interacting genes in the toll-like receptor signaling pathway and the an...
21043546 - Tdap5 vaccine (covaxis): a review of its use as a single-booster immunization for the p...
11821766 - Biomechanical properties of tissue-engineered cartilage from human and rabbit chondrocy...
3541426 - Intradermal hepatitis b vaccination in an abbreviated schedule.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Advances in therapy     Volume:  24     ISSN:  0741-238X     ISO Abbreviation:  Adv Ther     Publication Date:    2007 Mar-Apr
Date Detail:
Created Date:  2007-06-13     Completed Date:  2007-07-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  353-61     Citation Subset:  T    
Affiliation:
Department of Pediatrics, University of Calgary, Alberta Children's Hospital, The Children's Clinic Calgary, Alberta, Canada. aleung@ucalgary.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Anti-Bacterial Agents / therapeutic use
Communicable Disease Control
Communicable Diseases / drug therapy,  epidemiology
Humans
Macrolides / therapeutic use
Pertussis Vaccine*
Whooping Cough / drug therapy,  epidemiology*,  prevention & control*
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Macrolides; 0/Pertussis Vaccine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood press...
Next Document:  Pregnancy-associated plasma protein-A and asthma.